TARCEVA (erlotinib tablets) Patient Assistance Program
Don’t let the high cost of brand EGFR tyrosine kinase inhibitor disrupt your lung or pancreatic cancer treatment. We help eligible patients access Tarceva (erlotinib tablets) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program — or via the widely available generic.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Tarceva (erlotinib) is FDA-approved for first-line treatment of metastatic NSCLC with EGFR exon 19 deletion or L858R substitution mutations, and in combination with gemcitabine for first-line treatment of locally advanced, unresectable, or metastatic pancreatic cancer. First-generation oral EGFR tyrosine kinase inhibitor.
- Without assistance, brand Tarceva costs commonly run approximately $5,000–$7,000 per month.
- Through AffordMyPrescriptions, qualifying patients can access Tarceva for a flat $69.95 per month.
- **Generic erlotinib widely available — substantial savings vs brand Tarceva (~$200–$400/month).** For first-line common-mutation EGFR NSCLC, the FLAURA trial established Tagrisso (osimertinib — third-generation EGFR TKI) as superior to erlotinib/gefitinib in overall survival, with better tolerability and CNS penetration — making Tagrisso the current first-line standard. Erlotinib remains useful in specific clinical situations (Tagrisso unavailable, contraindication, prior progression management) and as cost-effective option globally. For EGFR exon 20 insertions: Rybrevant ± Lazcluze (not standard EGFR TKIs). Other EGFR TKIs: gefitinib (Iressa — generic), afatinib (Gilotrif), dacomitinib (Vizimpro). For pancreatic cancer beyond erlotinib + gemcitabine: gemcitabine + nab-paclitaxel (gemcitabine + Abraxane), FOLFIRINOX (generic chemo backbone), Lynparza for germline BRCA-mutated maintenance after platinum. Tumor molecular profiling essential for NSCLC treatment selection.
What is Tarceva Prescription Assistance Program?
The Tarceva Patient Assistance Program is a manufacturer-sponsored initiative that helps eligible patients access Tarceva (used for EGFR-mutated non-small cell lung cancer and pancreatic cancer) at little or no cost when they meet specific income, insurance, and clinical criteria. The program is free to apply for, but the enrollment process involves detailed applications, oncology coordination, EGFR mutation testing documentation (for NSCLC), supporting documentation, and ongoing renewal — which can be overwhelming when you are managing lung or pancreatic cancer.
At AffordMyPrescriptions, our Patient Advocates handle the entire Tarceva PAP enrollment for a flat $69.95 per month. We complete the application, coordinate with your oncologist for required medical documentation, follow up with the manufacturer’s program until approval, manage your refills, and handle annual re-certification — so you never face a gap in your Tarceva EGFR TKI therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Tarceva enrollment — from the initial application through ongoing refills and annual re-enrollment — so you never face a gap in your cancer treatment.
Pharmacy Price Comparison
- Without assistance, brand Tarceva costs thousands of dollars per month at specialty pharmacies. Generic erlotinib offers substantial savings, but a Patient Assistance Program can further reduce cost. The table below compares typical retail pricing across major pharmacies to what you'd pay with our Tarceva advocacy service:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens (brand) | ~$6,700/mo | Save substantially |
| CVS Pharmacy(brand) | ~$7,000/mo | Save substantially |
| Walmart(brand) | ~$5,200/mo | Save substantially |
| Specialty pharmacy (brand) | ~$5,000/mo | Save substantially |
| Generic erlotinib | ~$300/mo | Generic — substantial |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Tarceva — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Tarceva Prescription Program ?
The Tarceva Patient Assistance Program is free to apply and provides medication at no cost if approved. But the process involves detailed applications, prescriber coordination, documentation, and ongoing management — applications that are commonly delayed or denied when paperwork is incomplete. Our $69.95 per month covers full advocacy: applications, doctor coordination, documentation, refill management, and re-enrollment — so you focus on your health, not paperwork. Generic erlotinib is now substantially cheaper than brand Tarceva, and Tagrisso (osimertinib) is the first-line standard for common-mutation EGFR NSCLC.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Tarceva:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
- Still $5,000–$7,000 per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Tarceva assistance.
- You are a U.S. citizen or legal resident
- You Have A Valid Tarceva Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Tarceva:
Tarceva (erlotinib) was an important early breakthrough in targeted lung cancer therapy — the first oral EGFR TKI shown to benefit EGFR-mutated NSCLC. With the development of third-generation EGFR TKIs (osimertinib/Tagrisso) demonstrating superior overall survival in first-line common-mutation EGFR NSCLC, Tagrisso has become standard first-line therapy. Erlotinib (Tarceva or generic) remains useful in specific clinical situations and as a cost-effective option in pancreatic cancer combination therapy.
How Tarceva works:
EGFR (epidermal growth factor receptor) drives tumor growth in EGFR-mutated non-small cell lung cancer and contributes to pancreatic cancer biology. Common EGFR mutations (exon 19 deletion, L858R) are sensitive to EGFR TKI therapy.
Erlotinib is an oral, reversible inhibitor of EGFR tyrosine kinase activity — blocks downstream signaling that drives cancer cell proliferation. In EGFR-mutated NSCLC, response rates are 60–70%+ in treatment-naive patients, but resistance typically emerges within 9–14 months (often through T790M mutation, addressed by osimertinib/Tagrisso). Modest benefit in pancreatic cancer when combined with gemcitabine. Newer-generation TKIs (afatinib, dacomitinib, osimertinib) offer improved outcomes in NSCLC.
Form and use:
Tarceva 25 mg, 100 mg, or 150 mg tablets. NSCLC: 150 mg once daily. Pancreatic cancer: 100 mg once daily with gemcitabine. **Take on empty stomach — at least 1 hour before or 2 hours after food** (food significantly increases erlotinib absorption and exposure). Continue until disease progression or unacceptable toxicity. Hold for grade 3+ rash, diarrhea, or other toxicity. Avoid smoking (induces CYP1A2, reducing erlotinib levels significantly). Avoid strong CYP3A4 inhibitors or inducers.
Generic availability:
**Generic erlotinib widely available — substantial savings vs brand Tarceva (~$200–$400/month).** Other EGFR TKIs: osimertinib (Tagrisso — third-generation, current first-line standard for common-mutation EGFR NSCLC per FLAURA), gefitinib (Iressa — generic, first-generation similar to erlotinib), afatinib (Gilotrif — second-generation, generic in some markets), dacomitinib (Vizimpro). For EGFR exon 20 insertions: Rybrevant (amivantamab) ± Lazcluze. For ALK rearrangement: alectinib, lorlatinib, brigatinib, ceritinib, crizotinib. For ROS1: entrectinib, crizotinib, lorlatinib, repotrectinib. For BRAF V600E: dabrafenib + trametinib. For other oncogenes: capmatinib, tepotinib, trastuzumab deruxtecan, selpercatinib/pralsetinib, KRAS G12C inhibitors. For wild-type NSCLC: pembrolizumab (Keytruda) ± chemo, atezolizumab, durvalumab, nivolumab + ipilimumab. For pancreatic cancer: gemcitabine + nab-paclitaxel (gemcitabine + Abraxane), FOLFIRINOX (generic chemo backbone), Lynparza for germline BRCA-mutated maintenance after platinum.
Warnings:
**Interstitial lung disease and pneumonitis (sometimes fatal — evaluate any new respiratory symptoms), hepatotoxicity (monitor LFTs, especially with pre-existing hepatic impairment), renal failure (rare), GI perforation (rare), severe skin reactions (bullous, blistering, exfoliative — including SJS/TEN, rare), ocular disorders (corneal perforation/ulceration, abnormal eyelash growth — discontinue if severe), MI/CVA in pancreatic cancer (numerical increase in trial), microangiopathic hemolytic anemia with thrombocytopenia, hemorrhage with concurrent anticoagulation.** Common: rash (acneiform — very common, often a marker of response), diarrhea, anorexia, fatigue, dyspnea, cough, nausea, vomiting, mucositis, stomatitis. Drug interactions: strong CYP3A4 inhibitors (azoles, clarithromycin, ritonavir, grapefruit) increase erlotinib — caution; strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St. John’s wort) reduce efficacy — avoid; smoking (CYP1A2 induction) reduces erlotinib levels significantly; PPIs and H2 blockers can reduce erlotinib absorption (acidic environment needed) — avoid concurrent use.
FAQ (Frequently Asked Questions)
How much does Tarceva cost without insurance?
Brand-name Tarceva costs approximately $2,874–$8,909 per month depending on dose. Generic erlotinib is available for as little as $92–$223 per month with coupons. Through AffordMyPrescriptions, qualifying patients can access brand Tarceva at no medication cost, or we’ll help you find the lowest coupon price for generic erlotinib — our $69.95 monthly fee covers advocacy.
Is brand Tarceva better than the generic version?
Generic erlotinib is FDA-approved bioequivalent to brand Tarceva. Same active ingredient, same effect, same safety profile. Most patients can use the generic without clinical difference at a tiny fraction of brand cost. Brand offers no clinical advantage.
What is the difference between Tarceva (erlotinib) and Tagrisso (osimertinib)?
Both target EGFR-mutated NSCLC. Tarceva is a first-generation EGFR TKI; Tagrisso is third-generation — selective for activating mutations and T790M resistance mutation, with better CNS penetration and tolerability. The FLAURA trial established Tagrisso as superior to erlotinib/gefitinib for first-line common-mutation EGFR NSCLC in overall survival. Tagrisso is current first-line standard; erlotinib/generic remains useful in specific clinical situations and as cost-effective alternative globally.
Why aren't newer EGFR TKIs like Tagrisso tried as first-line instead of erlotinib?
They typically are — Tagrisso (osimertinib) is current first-line standard per NCCN guidelines for common-mutation EGFR NSCLC. Erlotinib/generic is used in specific clinical situations (Tagrisso unavailable, contraindications, payer issues) and globally as a cost-effective option. After Tagrisso progression, erlotinib is generally not used (different resistance pattern).
Is Tarceva considered chemotherapy?
No — Tarceva is a targeted oral therapy (EGFR tyrosine kinase inhibitor) — not traditional cytotoxic chemotherapy. Different toxicity profile, especially skin (acneiform rash) and GI (diarrhea) effects.
Why does Tarceva need to be taken on an empty stomach?
Food significantly increases erlotinib absorption — leading to higher levels and increased toxicity risk. Taking on empty stomach (at least 1 hour before or 2 hours after food) provides predictable, controlled exposure. PPIs and H2 blockers can reduce erlotinib absorption — avoid concurrent acid suppression.
Why is smoking a concern with Tarceva?
Smoking induces CYP1A2 metabolism, significantly reducing erlotinib levels — potentially reducing efficacy. Patients should be counseled about the importance of smoking cessation while on erlotinib (and for general lung cancer management).
What happens if my Tarceva Patient Assistance Program application is denied?
We help explore **generic erlotinib (substantial savings)**, Tagrisso copay programs (preferred first-line for common-mutation EGFR NSCLC), other EGFR TKIs in appropriate clinical contexts, generic gemcitabine + nab-paclitaxel for pancreatic cancer, FOLFIRINOX combinations, Lynparza for germline BRCA-mutated pancreatic cancer maintenance, manufacturer copay programs, Lung Cancer Research Foundation, LUNGevity, Pancreatic Cancer Action Network, Patient Access Network, Patient Advocate Foundation, CancerCare, NeedyMeds, and Medicare Part D Extra Help and state SPAP programs.
Take Control of Your Medication Costs
Targeted EGFR TKI therapy for lung and pancreatic cancer should not be derailed by cost. Generic erlotinib offers substantial savings vs brand Tarceva, and Tagrisso is the preferred first-line for common-mutation EGFR NSCLC. Our Tarceva advocacy team is ready to verify your eligibility, complete the manufacturer application on your behalf, and manage your prescription through approval, delivery, and renewal — for a flat $69.95 per month. If we cannot help you access Tarceva through a Patient Assistance Program, you are not charged. Call (833) 556-2729 or check your eligibility online today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.